Palisade Bio Inc. (PALI) Appoints Brian Feagan to its Board

Palisade Bio, Inc. (Nasdaq: PALI) today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.

Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn’s disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated much of his career to developing, validating, and optimizing outcome measures to evaluate the efficacy of novel therapeutics in CD and UC.

“We are thrilled to welcome Dr. Feagan to our Clinical Advisory Board,” said JD Finley, Chief Executive Officer of Palisade Bio. “Dr. Feagan’s extensive research experience in CD and UC, along with his deep expertise in clinical trial design, will be invaluable as we advance the development of our next-generation precision therapies, beginning with PALI-2108 for the treatment of ulcerative colitis.”

Dr. Feagan commented, “Patients and clinicians are increasingly seeking oral treatment options that are more effective, safe and well-tolerated. PALI-2108’s localized bioactivation holds the potential to address the tolerability issues associated with systemic distribution of this class of therapeutics. I look forward to collaborating with the Company to explore the most effective strategies for demonstrating clinical efficacy and advancing the development of this promising candidate, which targets significant unmet medical needs.”

You May Also Be Interested In

• FutureFuel director Paul Manheim to retire from board in 2026
• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• TEN Holdings prices $7.5 million common stock offering at $1 per share